Loading
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
Declan Murphy was co-principal investigator of proPSMA, the randomised trial showing PSMA PET-CT is 27% more accurate than conventional imaging for staging high-risk prostate cancer, the evidence behind PSMA PET's adoption in guidelines. He directs GU oncology at Peter Mac, leads robotic surgery, and chairs the ANZUP theranostics and surgical sub-committees.
| Title | Journal | Year |
|---|---|---|
| Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA) | Lancet | 2020 |
| Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis | European Urology | 2020 |
Shares proPSMA, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA.
Shares European Urology, PSMA, PSMA PET, Prostate cancer and the tag prostate.
Shares Robotic & minimally invasive surgery, Prostate cancer and the tags prostate, surgery.
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA, Prostate cancer.
Shares proPSMA, ANZUP Cancer Trials Group, Prostate cancer.
Shares European Urology, Robotic & minimally invasive surgery and the tag surgery.
Shares Prostate cancer and the tags prostate, imaging.
Shares Prostate cancer and the tags prostate, imaging.